Is Alzheimer’s Disease Autoimmune Inflammation of the Brain That Can be Treated With Nasal Nonsteroidal Anti-Inflammatory Drugs?
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The Alzheimer’s Association recently reported that a woman’s estimated lifetime risk of developing Alzheimer’s at age 65 is 1 in 6, compared to nearly 1 in 11 for a man (ie, female to male ratio 1.8). Based on female to male ratio, Alzheimer’s disease could well be an autoimmune disorder. Like Alzheimer’s, multiple sclerosis, an autoimmune inflammation of the central nervous system, has a female to male ratio of 2.3. Also based on female to male ratio, Alzheimer’s resembles the autoimmune inflammatory disease rheumatoid arthritis, which has a female to male ratio of 2.7. The reasons for the female preponderance in autoimmune disease are unclear, but nonsteroidal anti-inflammatory drugs (NSAIDs) are widely and successfully employed to treat autoimmune anti-inflammatory disease and dramatically relieve symptoms. Moreover, oral NSAIDs consistently reduce the risk of Alzheimer’s disease, although they have been totally ineffective as a treatment in multiple failed clinical trials. A basis for this failure might well be that the brain dose after oral administration is too small and not sufficiently early in the pathogenesis of the disorder. But NSAID brain dose could be significantly increased by delivering the NSAIDs intranasally.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Lindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities
Tabas, I., & Glass, C. K. (2013) · Science · doi:10.1126/science.1230720 · Cited by 1,093
Multiple sclerosis: a complicated picture of autoimmunity
McFarland, H. F., & Martin, R. (2007) · Nature Immunology · doi:10.1038/ni1507 · Cited by 985
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · cited 1×
“Long-term use of anti-inflammatory drugs is linked with reduced risk of developing Alzheimer’s disease.(4) Amyloid-b plaques and t protein tangles, hallmarks of the pathology, are most likely a nonspecific result of the disease process, rather than a cause.”
BackgroundThe Preclinical Phase of Alzheimer Disease: A 22-Year Prospective Study of the Framingham Cohort
Elias, M. F., Beiser, A., Wolf, P. A., Au, R., White, R. F., & D'Agostino, R. B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.808 · Cited by 716 · cited 1×
“But in Alzheimer’s disease, the preclinical phase of detectable lowering of cognitive functioning precedes the appearance of clinical disease by many years.(20,21)”
BackgroundGender and incidence of dementia in the Framingham Heart Study from mid‐adult life
Chêne, G., Beiser, A., Au, R., Preis, S. R., Wolf, P. A., Dufouil, C., & Seshadri, S. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.005 · Cited by 499
The microglial phagocytic role with specific plaque types in the Alzheimer disease brain
D’Andrea, M. R., Cole, G. M., & Ard, M. D. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.026 · Cited by 215
Marchetti, B., & Abbracchio, M. P. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.08.007 · Cited by 175 · cited 1×
“Indeed, NSAIDs can restore neurogenesis through attenuation of microgliosis.(33) If animal studies can validate the nasal route as a means of delivering a specific NSAID to the entorhinal cortex, then a trial of an intranasal formulation of that NSAID may be justified.”
Background
Cited by
Zhang, J., Zheng, Y., Luo, Y., Du, Y., Zhang, X., & Fu, J. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.09.020 · Cited by 464
Hanamsagar, R., & Bilbo, S. D. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.09.039 · Cited by 374
Thomas, J., Thomas, C. J., Radcliffe, J., & Itsiopoulos, C. (2015) · BioMed Research International · doi:10.1155/2015/172801 · Cited by 173
Duma, C., Kopyov, O., Kopyov, A., Berman, M., Lander, E., Elam, M., Arata, M., Weiland, D., Cannell, R., Caraway, C., et al. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04983-5 · Cited by 85
Daulatzai, M. A. (2015) · Neurotoxicity Research · doi:10.1007/s12640-015-9528-x · Cited by 12
“Indeed, the single medication or single treatment modality has failed to ameliorate the heterogeneous pathologies encountered in AD (Aisen et al. 2008; Aisen and Vellas 2013; Doody et al. 2013; Lehrer and Rheinstein 2014).”
Background
Metadata
- Authors
- Lehrer, S., & Rheinstein, P. H.
- Venue
- American Journal of Alzheimer's Disease & Other Dementias®
- Publisher
- SAGE Publications
- Published
- 2014-08-05
- Volume
- 30
- Issue
- 3
- Pages
- 225-227
- ISSN
- 0888-4897 (ISSN-L)
- 1533-3175
- 1938-2731
- OpenAlex
- W2082340799
- Cited by
- 22
- References
- 11
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is Alzheimer’s Disease Autoimmune Inflammation of the Brain That Can be Treated With Nasal Nonsteroidal Anti-Inflammatory Drugs? https://app.cochat.ai/papers/10.1177/1533317514545478
- The paper
- Lehrer, S., & Rheinstein, P. H. (2015). Is Alzheimer’s Disease Autoimmune Inflammation of the Brain That Can be Treated With Nasal Nonsteroidal Anti-Inflammatory Drugs? American Journal of Alzheimer's Disease & Other Dementias®. https://doi.org/10.1177/1533317514545478
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.